Clinical presentation of carcinoma of unknown primary: 14 years of experience
A carcinoma of unknown primary (CUP) is a histologically confirmed metastatic cancer without a definitive primary site after performing a detailed medical examination. The purpose of the study was to classify unfavorable CUPs into more reliable disease entities, which reflect the clinical course. We...
Gespeichert in:
| Veröffentlicht in: | Tumor biology 2011-02, Vol.32 (1), p.45-51 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 51 |
|---|---|
| container_issue | 1 |
| container_start_page | 45 |
| container_title | Tumor biology |
| container_volume | 32 |
| creator | Yi, Jun Ho La Choi, Yoon Lee, Su Jin Ahn, Hee Kyung Baek, Kyung Kee Lim, TaeKyu Lee, Duk Joo Han, Bo Ram Lee, Ha Yeon Jun, Hyun Jung Lee, Jeeyun Park, Yeon Hee |
| description | A carcinoma of unknown primary (CUP) is a histologically confirmed metastatic cancer without a definitive primary site after performing a detailed medical examination. The purpose of the study was to classify unfavorable CUPs into more reliable disease entities, which reflect the clinical course. We reviewed the medical records of patients diagnosed with a CUP between January 1995 and March 2008. Patients were classified into a conventional favorable-risk group and a newly proposed unfavorable-risk group according to the clinicopathologic features. Five hundred eighty-six patients were diagnosed with CUPs. Fifty-six (9.6%) patients were classified in the conventional favorable-risk group, and 486 (82.9%) patients were classified in the unfavorable-risk group. We further classified the 486 patients into six subgroups with an unfavorable risk, while excluding 29 patients (5.0%) who were not classifiable. The overall survival of the conventional favorable-risk group was 47.0 months (95% CI, 11.1~82.9 months), which was significantly longer than that of any subgroup of the newly proposed unfavorable-risk group (
P
|
| doi_str_mv | 10.1007/s13277-010-0089-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_818645933</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2248827311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c370t-802d7ea429bab20c6c6c1e978289acd17da1bdf15261b3dce0d24836303f896c3</originalsourceid><addsrcrecordid>eNp1kE1OwzAQhS0EoqVwADaoYsMqMLZT_7BDFX8Sgg2sLceZoJTUKXYj6G04CyfDUQtISMiLsfW-eZ55hBxSOKUA8ixSzqTMgEIGoHQmtsiQ5oxnwBVsp3uv5EzxAdmLcQZAJ1qLXTJgILTUSgzJ_bSpfe1sM14EjOiXdlm3ftxWY2eDq307t_2j8y--ffMJquc2rM7HNP_8WKENsVfxfYGhRu9wn-xUtol4sKkj8nR1-Ti9ye4erm-nF3eZ4xKWmQJWSrQ504UtGDiRDkUtFVPaupLK0tKirOiECVrw0iGULFdccOCV0sLxETlZ-y5C-9phXJp5HR02jfXYdtEoqkQ-0Zwn8vgPOWu74NNwRuUyTcOoShBdQy60MQaszGZRQ8H0UZt11CYFavqojUg9Rxvjrphj-dPxnW0C2BqISfLPGH5__t_1C3fsiVE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>847370218</pqid></control><display><type>article</type><title>Clinical presentation of carcinoma of unknown primary: 14 years of experience</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Yi, Jun Ho ; La Choi, Yoon ; Lee, Su Jin ; Ahn, Hee Kyung ; Baek, Kyung Kee ; Lim, TaeKyu ; Lee, Duk Joo ; Han, Bo Ram ; Lee, Ha Yeon ; Jun, Hyun Jung ; Lee, Jeeyun ; Park, Yeon Hee</creator><creatorcontrib>Yi, Jun Ho ; La Choi, Yoon ; Lee, Su Jin ; Ahn, Hee Kyung ; Baek, Kyung Kee ; Lim, TaeKyu ; Lee, Duk Joo ; Han, Bo Ram ; Lee, Ha Yeon ; Jun, Hyun Jung ; Lee, Jeeyun ; Park, Yeon Hee</creatorcontrib><description>A carcinoma of unknown primary (CUP) is a histologically confirmed metastatic cancer without a definitive primary site after performing a detailed medical examination. The purpose of the study was to classify unfavorable CUPs into more reliable disease entities, which reflect the clinical course. We reviewed the medical records of patients diagnosed with a CUP between January 1995 and March 2008. Patients were classified into a conventional favorable-risk group and a newly proposed unfavorable-risk group according to the clinicopathologic features. Five hundred eighty-six patients were diagnosed with CUPs. Fifty-six (9.6%) patients were classified in the conventional favorable-risk group, and 486 (82.9%) patients were classified in the unfavorable-risk group. We further classified the 486 patients into six subgroups with an unfavorable risk, while excluding 29 patients (5.0%) who were not classifiable. The overall survival of the conventional favorable-risk group was 47.0 months (95% CI, 11.1~82.9 months), which was significantly longer than that of any subgroup of the newly proposed unfavorable-risk group (
P
< 0.001). Patients with squamous cell carcinoma in the abdominopelvic cavity showed similar overall survival with unfavorable-risk group (
P
= 0.484). Women with non-papillary malignant ascites had a survival in between the favorable and unfavorable groups (
P
< 0.001). The newly proposed unfavorable-risk group may assist in classifying CUP patients with an unfavorable risk in a clinically more meaningful way. Squamous cell carcinoma in the abdominopelvic cavity should be considered in the unfavorable-risk group and women with non-papillary malignant ascites in an intermediate-risk group. Further studies with molecular profiling would help in classifying and treating patients with CUPs and an unfavorable risk.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-010-0089-6</identifier><identifier>PMID: 20697986</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adenocarcinoma - classification ; Adenocarcinoma - secondary ; Adult ; Aged ; Aged, 80 and over ; Biomedical and Life Sciences ; Biomedicine ; Bone Neoplasms - classification ; Bone Neoplasms - secondary ; Cancer ; Cancer Research ; Carcinoma, Squamous Cell - classification ; Carcinoma, Squamous Cell - secondary ; Cohort Studies ; Female ; Humans ; Male ; Medical prognosis ; Middle Aged ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Staging ; Neoplasms, Unknown Primary - classification ; Neoplasms, Unknown Primary - diagnosis ; Prognosis ; Research Article ; Risk factors ; Survival analysis ; Survival Rate ; Young Adult</subject><ispartof>Tumor biology, 2011-02, Vol.32 (1), p.45-51</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2010</rights><rights>International Society of Oncology and BioMarkers (ISOBM) 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c370t-802d7ea429bab20c6c6c1e978289acd17da1bdf15261b3dce0d24836303f896c3</citedby><cites>FETCH-LOGICAL-c370t-802d7ea429bab20c6c6c1e978289acd17da1bdf15261b3dce0d24836303f896c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13277-010-0089-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13277-010-0089-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20697986$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yi, Jun Ho</creatorcontrib><creatorcontrib>La Choi, Yoon</creatorcontrib><creatorcontrib>Lee, Su Jin</creatorcontrib><creatorcontrib>Ahn, Hee Kyung</creatorcontrib><creatorcontrib>Baek, Kyung Kee</creatorcontrib><creatorcontrib>Lim, TaeKyu</creatorcontrib><creatorcontrib>Lee, Duk Joo</creatorcontrib><creatorcontrib>Han, Bo Ram</creatorcontrib><creatorcontrib>Lee, Ha Yeon</creatorcontrib><creatorcontrib>Jun, Hyun Jung</creatorcontrib><creatorcontrib>Lee, Jeeyun</creatorcontrib><creatorcontrib>Park, Yeon Hee</creatorcontrib><title>Clinical presentation of carcinoma of unknown primary: 14 years of experience</title><title>Tumor biology</title><addtitle>Tumor Biol</addtitle><addtitle>Tumour Biol</addtitle><description>A carcinoma of unknown primary (CUP) is a histologically confirmed metastatic cancer without a definitive primary site after performing a detailed medical examination. The purpose of the study was to classify unfavorable CUPs into more reliable disease entities, which reflect the clinical course. We reviewed the medical records of patients diagnosed with a CUP between January 1995 and March 2008. Patients were classified into a conventional favorable-risk group and a newly proposed unfavorable-risk group according to the clinicopathologic features. Five hundred eighty-six patients were diagnosed with CUPs. Fifty-six (9.6%) patients were classified in the conventional favorable-risk group, and 486 (82.9%) patients were classified in the unfavorable-risk group. We further classified the 486 patients into six subgroups with an unfavorable risk, while excluding 29 patients (5.0%) who were not classifiable. The overall survival of the conventional favorable-risk group was 47.0 months (95% CI, 11.1~82.9 months), which was significantly longer than that of any subgroup of the newly proposed unfavorable-risk group (
P
< 0.001). Patients with squamous cell carcinoma in the abdominopelvic cavity showed similar overall survival with unfavorable-risk group (
P
= 0.484). Women with non-papillary malignant ascites had a survival in between the favorable and unfavorable groups (
P
< 0.001). The newly proposed unfavorable-risk group may assist in classifying CUP patients with an unfavorable risk in a clinically more meaningful way. Squamous cell carcinoma in the abdominopelvic cavity should be considered in the unfavorable-risk group and women with non-papillary malignant ascites in an intermediate-risk group. Further studies with molecular profiling would help in classifying and treating patients with CUPs and an unfavorable risk.</description><subject>Adenocarcinoma - classification</subject><subject>Adenocarcinoma - secondary</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bone Neoplasms - classification</subject><subject>Bone Neoplasms - secondary</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Carcinoma, Squamous Cell - classification</subject><subject>Carcinoma, Squamous Cell - secondary</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Staging</subject><subject>Neoplasms, Unknown Primary - classification</subject><subject>Neoplasms, Unknown Primary - diagnosis</subject><subject>Prognosis</subject><subject>Research Article</subject><subject>Risk factors</subject><subject>Survival analysis</subject><subject>Survival Rate</subject><subject>Young Adult</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kE1OwzAQhS0EoqVwADaoYsMqMLZT_7BDFX8Sgg2sLceZoJTUKXYj6G04CyfDUQtISMiLsfW-eZ55hBxSOKUA8ixSzqTMgEIGoHQmtsiQ5oxnwBVsp3uv5EzxAdmLcQZAJ1qLXTJgILTUSgzJ_bSpfe1sM14EjOiXdlm3ftxWY2eDq307t_2j8y--ffMJquc2rM7HNP_8WKENsVfxfYGhRu9wn-xUtol4sKkj8nR1-Ti9ye4erm-nF3eZ4xKWmQJWSrQ504UtGDiRDkUtFVPaupLK0tKirOiECVrw0iGULFdccOCV0sLxETlZ-y5C-9phXJp5HR02jfXYdtEoqkQ-0Zwn8vgPOWu74NNwRuUyTcOoShBdQy60MQaszGZRQ8H0UZt11CYFavqojUg9Rxvjrphj-dPxnW0C2BqISfLPGH5__t_1C3fsiVE</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>Yi, Jun Ho</creator><creator>La Choi, Yoon</creator><creator>Lee, Su Jin</creator><creator>Ahn, Hee Kyung</creator><creator>Baek, Kyung Kee</creator><creator>Lim, TaeKyu</creator><creator>Lee, Duk Joo</creator><creator>Han, Bo Ram</creator><creator>Lee, Ha Yeon</creator><creator>Jun, Hyun Jung</creator><creator>Lee, Jeeyun</creator><creator>Park, Yeon Hee</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20110201</creationdate><title>Clinical presentation of carcinoma of unknown primary: 14 years of experience</title><author>Yi, Jun Ho ; La Choi, Yoon ; Lee, Su Jin ; Ahn, Hee Kyung ; Baek, Kyung Kee ; Lim, TaeKyu ; Lee, Duk Joo ; Han, Bo Ram ; Lee, Ha Yeon ; Jun, Hyun Jung ; Lee, Jeeyun ; Park, Yeon Hee</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c370t-802d7ea429bab20c6c6c1e978289acd17da1bdf15261b3dce0d24836303f896c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adenocarcinoma - classification</topic><topic>Adenocarcinoma - secondary</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bone Neoplasms - classification</topic><topic>Bone Neoplasms - secondary</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Carcinoma, Squamous Cell - classification</topic><topic>Carcinoma, Squamous Cell - secondary</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Staging</topic><topic>Neoplasms, Unknown Primary - classification</topic><topic>Neoplasms, Unknown Primary - diagnosis</topic><topic>Prognosis</topic><topic>Research Article</topic><topic>Risk factors</topic><topic>Survival analysis</topic><topic>Survival Rate</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yi, Jun Ho</creatorcontrib><creatorcontrib>La Choi, Yoon</creatorcontrib><creatorcontrib>Lee, Su Jin</creatorcontrib><creatorcontrib>Ahn, Hee Kyung</creatorcontrib><creatorcontrib>Baek, Kyung Kee</creatorcontrib><creatorcontrib>Lim, TaeKyu</creatorcontrib><creatorcontrib>Lee, Duk Joo</creatorcontrib><creatorcontrib>Han, Bo Ram</creatorcontrib><creatorcontrib>Lee, Ha Yeon</creatorcontrib><creatorcontrib>Jun, Hyun Jung</creatorcontrib><creatorcontrib>Lee, Jeeyun</creatorcontrib><creatorcontrib>Park, Yeon Hee</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yi, Jun Ho</au><au>La Choi, Yoon</au><au>Lee, Su Jin</au><au>Ahn, Hee Kyung</au><au>Baek, Kyung Kee</au><au>Lim, TaeKyu</au><au>Lee, Duk Joo</au><au>Han, Bo Ram</au><au>Lee, Ha Yeon</au><au>Jun, Hyun Jung</au><au>Lee, Jeeyun</au><au>Park, Yeon Hee</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical presentation of carcinoma of unknown primary: 14 years of experience</atitle><jtitle>Tumor biology</jtitle><stitle>Tumor Biol</stitle><addtitle>Tumour Biol</addtitle><date>2011-02-01</date><risdate>2011</risdate><volume>32</volume><issue>1</issue><spage>45</spage><epage>51</epage><pages>45-51</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>A carcinoma of unknown primary (CUP) is a histologically confirmed metastatic cancer without a definitive primary site after performing a detailed medical examination. The purpose of the study was to classify unfavorable CUPs into more reliable disease entities, which reflect the clinical course. We reviewed the medical records of patients diagnosed with a CUP between January 1995 and March 2008. Patients were classified into a conventional favorable-risk group and a newly proposed unfavorable-risk group according to the clinicopathologic features. Five hundred eighty-six patients were diagnosed with CUPs. Fifty-six (9.6%) patients were classified in the conventional favorable-risk group, and 486 (82.9%) patients were classified in the unfavorable-risk group. We further classified the 486 patients into six subgroups with an unfavorable risk, while excluding 29 patients (5.0%) who were not classifiable. The overall survival of the conventional favorable-risk group was 47.0 months (95% CI, 11.1~82.9 months), which was significantly longer than that of any subgroup of the newly proposed unfavorable-risk group (
P
< 0.001). Patients with squamous cell carcinoma in the abdominopelvic cavity showed similar overall survival with unfavorable-risk group (
P
= 0.484). Women with non-papillary malignant ascites had a survival in between the favorable and unfavorable groups (
P
< 0.001). The newly proposed unfavorable-risk group may assist in classifying CUP patients with an unfavorable risk in a clinically more meaningful way. Squamous cell carcinoma in the abdominopelvic cavity should be considered in the unfavorable-risk group and women with non-papillary malignant ascites in an intermediate-risk group. Further studies with molecular profiling would help in classifying and treating patients with CUPs and an unfavorable risk.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>20697986</pmid><doi>10.1007/s13277-010-0089-6</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1010-4283 |
| ispartof | Tumor biology, 2011-02, Vol.32 (1), p.45-51 |
| issn | 1010-4283 1423-0380 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_818645933 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adenocarcinoma - classification Adenocarcinoma - secondary Adult Aged Aged, 80 and over Biomedical and Life Sciences Biomedicine Bone Neoplasms - classification Bone Neoplasms - secondary Cancer Cancer Research Carcinoma, Squamous Cell - classification Carcinoma, Squamous Cell - secondary Cohort Studies Female Humans Male Medical prognosis Middle Aged Neoplasm Recurrence, Local - diagnosis Neoplasm Staging Neoplasms, Unknown Primary - classification Neoplasms, Unknown Primary - diagnosis Prognosis Research Article Risk factors Survival analysis Survival Rate Young Adult |
| title | Clinical presentation of carcinoma of unknown primary: 14 years of experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T05%3A29%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20presentation%20of%20carcinoma%20of%20unknown%20primary:%2014%C2%A0years%20of%20experience&rft.jtitle=Tumor%20biology&rft.au=Yi,%20Jun%20Ho&rft.date=2011-02-01&rft.volume=32&rft.issue=1&rft.spage=45&rft.epage=51&rft.pages=45-51&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-010-0089-6&rft_dat=%3Cproquest_cross%3E2248827311%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=847370218&rft_id=info:pmid/20697986&rfr_iscdi=true |